| Original language | English (US) |
|---|---|
| Pages (from-to) | 296-298 |
| Number of pages | 3 |
| Journal | JAMA Oncology |
| Volume | 6 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2020 |
| Externally published | Yes |
Bibliographical note
Funding Information:Conflict of Interest Disclosures: Dr Ali reported grants and personal fees from Celgene, personal fees from Bristol-Myers Squibb, grants and personal fees from Aduro Biotech, personal fees from Sanofi, grants and personal fees from Amgen, and grants from Poseida Therapeutics. Dr Overton received funding (grant 5T32CA126607-10) from the National Institutes of Health. Dr Makary receives funding from the Laura and John Arnold Foundation. No other disclosures were reported. 1. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370-381. doi:10.1016/S1470-2045(18)30072-X 2. Chakraborty R, Majhail NS, Anwer F. Denosumab vs zoledronic acid for bone-targeted therapy in multiple myeloma: what are the unanswered questions? JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.1598 3. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment: a prospective 2-year clinical trial. J Bone Miner Res.2019. doi:10.1002/jbmr.3853 4. West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol. 2011;29(9):1095-1098. doi:10.1200/JCO.2010.33.5596 5. Goldstein DA. Denosumab for bone lesions in multiple myeloma: what is its value? Haematologica. 2018;103(5):753-754. doi:10.3324/haematol.2017.185264 6. Gyawali B, Tessema FA, Jung EH, Kesselheim AS. Assessing the justification, funding, success, and survival outcomes of randomized noninferiority trials of cancer drugs: a systematic review and pooled analysis. JAMA Netw Open. 2019; 2(8):e199570. doi:10.1001/jamanetworkopen.2019.9570
Funding Information:
Bristol-Myers Squibb, Eli Lilly and Company, and Medac; personal fees from Roche, Sanofi, Eli Lilly and Company, Merck Serono, Amgen, Servier Laboratories, Merck Sharp & Dohme, and Bristol-Myers Squibb; and his institution received research funding from Sanofi, Medac, and German Cancer Aid. Dr Rödel reported receiving research funding from German Cancer Aid. No other disclosures were reported. Funding/Support: The CAO/ARO/AIO-94 and CAO/ARO/AIO-04 trials were funded by grants (70-578, 106-757) of the German Cancer Aid.